Loading...

Intercept Pharmaceuticals

Nasdaq:ICPT
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ICPT
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print Invest
  • Intercept Pharmaceuticals has significant price volatility in the past 3 months.
ICPT Share Price and Events
Price Volatility
ICPT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Intercept Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Intercept Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Intercept Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Intercept Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $84.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intercept Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intercept Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ICPT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings () in USD $-14.00
NasdaqGS:ICPT Share Price ** NasdaqGS (2018-06-19) in USD $84.82
United States of America Biotechs Industry PE Ratio Median Figure of 71 Publicly-Listed Biotechs Companies 27.35x
United States of America Market PE Ratio Median Figure of 7,865 Publicly-Listed Companies 18.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intercept Pharmaceuticals.

NasdaqGS:ICPT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ICPT Share Price ÷ EPS (both in USD)

= 84.82 ÷ -14.00

-6.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intercept Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Intercept Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Intercept Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:ICPT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
50.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 51 Publicly-Listed Biotechs Companies 1.49x
United States of America Market PEG Ratio Median Figure of 5,963 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

NasdaqGS:ICPT PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -6.06x ÷ 50.5%

-0.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intercept Pharmaceuticals is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intercept Pharmaceuticals's assets?
Raw Data
NasdaqGS:ICPT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings () in USD $-2.06
NasdaqGS:ICPT Share Price * NasdaqGS (2018-06-19) in USD $84.82
United States of America Biotechs Industry PB Ratio Median Figure of 571 Publicly-Listed Biotechs Companies 4.25x
United States of America Market PB Ratio Median Figure of 13,233 Publicly-Listed Companies 1.75x
NasdaqGS:ICPT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ICPT Share Price ÷ Book Value per Share (both in USD)

= 84.82 ÷ -2.06

-41.1x

* Primary Listing of Intercept Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intercept Pharmaceuticals has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at Intercept Pharmaceuticals's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Intercept Pharmaceuticals's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Intercept Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Intercept Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intercept Pharmaceuticals expected to grow at an attractive rate?
  • Intercept Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3%.
Growth vs Market Checks
  • Intercept Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Intercept Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ICPT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ICPT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 50.5%
NasdaqGS:ICPT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 36%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.4%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 16.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 11.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ICPT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ICPT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 848 206 569 3
2021-12-31 622 -96 205 4
2020-12-31 322 -250 -178 7
2019-12-31 275 -268 -265 13
2018-12-31 179 -314 -312 15
NasdaqGS:ICPT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-03-31 146 -277 -352
2017-12-31 131 -265 -360
2017-09-30 107 -278 -369
2017-06-30 71 -334 -385
2017-03-31 46 -350 -376
2016-12-31 25 -342 -413
2016-09-30 12 -319 -381
2016-06-30 7 -240 -343
2016-03-31 2 -203 -314
2015-12-31 3 -163 -226
2015-09-30 3 -129 -173
2015-06-30 3 -120 -158

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intercept Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Intercept Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ICPT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Intercept Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ICPT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 18.24 18.24 18.24 1.00
2021-12-31 6.04 6.57 5.50 2.00
2020-12-31 -6.57 -2.93 -11.07 4.00
2019-12-31 -8.85 -7.07 -9.80 11.00
2018-12-31 -11.38 -10.37 -12.64 13.00
NasdaqGS:ICPT Past Financials Data
Date (Data in USD Millions) EPS *
2018-03-31 -14.00
2017-12-31 -14.38
2017-09-30 -14.78
2017-06-30 -15.49
2017-03-31 -15.18
2016-12-31 -16.74
2016-09-30 -15.52
2016-06-30 -14.05
2016-03-31 -12.92
2015-12-31 -9.56
2015-09-30 -7.54
2015-06-30 -7.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intercept Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Intercept Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intercept Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Intercept Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intercept Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intercept Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intercept Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intercept Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Intercept Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intercept Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ICPT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 145.87 -352.03 271.18 195.04
2017-12-31 130.96 -360.37 269.80 190.20
2017-09-30 107.08 -369.14 268.48 185.60
2017-06-30 70.92 -385.35 260.92 175.04
2017-03-31 45.55 -376.09 238.81 165.75
2016-12-31 24.95 -412.83 228.60 153.89
2016-09-30 11.59 -381.04 209.87 131.24
2016-06-30 6.86 -343.12 180.81 123.32
2016-03-31 1.78 -313.72 156.97 116.71
2015-12-31 2.78 -226.43 119.24 112.70
2015-09-30 2.78 -173.00 70.71 107.47
2015-06-30 2.78 -157.95 55.11 107.36
2015-03-31 2.78 -76.58 42.09 93.98
2014-12-31 1.74 -283.23 34.60 80.31
2014-09-30 1.70 -260.77 27.47 66.18
2014-06-30 1.66 -256.66 21.45 47.19
2014-03-31 1.62 -303.61 16.39 37.40
2013-12-31 1.62 -67.79 13.13 27.94
2013-09-30 1.62 -86.24 10.59 23.14
2013-06-30 1.74 -60.69 8.46 18.07
2013-03-31 2.09 -53.05 6.51 17.96
2012-12-31 2.45 -46.27 5.18 16.18
2012-09-30 2.80 -19.85 4.03 15.56
2012-06-30 2.92 -17.25 4.19 14.75
2012-03-31 2.36 -15.29 4.26 12.11
2011-12-31 1.81 -15.74 4.21 11.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intercept Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Intercept Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intercept Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intercept Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Intercept Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intercept Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intercept Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intercept Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Intercept Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Intercept Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intercept Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGS:ICPT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 -52.28 359.45 326.09
2017-12-31 16.39 355.68 414.92
2017-09-30 111.67 351.98 492.75
2017-06-30 169.70 348.37 550.31
2017-03-31 240.24 344.83 608.01
2016-12-31 314.93 341.36 689.39
2016-09-30 414.94 337.90 779.96
2016-06-30 416.67 0.00 439.49
2016-03-31 488.33 0.00 556.86
2015-12-31 602.15 0.00 628.06
2015-09-30 677.88 0.00 695.71
2015-06-30 722.94 0.00 732.32
2015-03-31 395.92 0.00 401.99
2014-12-31 230.89 0.00 239.72
2014-09-30 261.06 0.00 272.81
2014-06-30 289.94 0.00 299.03
2014-03-31 -153.74 0.00 134.11
2013-12-31 82.41 0.00 144.91
2013-09-30 90.96 0.00 156.75
2013-06-30 116.27 0.00 161.80
2013-03-31 60.80 0.00 104.22
2012-12-31 65.91 0.00 110.27
2012-09-30 15.64 0.00 36.05
2012-06-30 20.00 0.00 39.83
2012-03-31 -2.56 0.08 17.91
2011-12-31 -2.56 0.08 17.91
  • Intercept Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Intercept Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we analyse their runway based on operating expenses, which includes recurring G&A and R&D. Analysis based on the most recent financials.

  • Intercept Pharmaceuticals's cash level is insufficient to cover its current level of operating expenses for the upcoming year.
  • Intercept Pharmaceuticals's cash level is insufficient to cover its operating expenses for the upcoming year, if it continues to grow at historical rates of 25% each year.
X
Financial health checks
We assess Intercept Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intercept Pharmaceuticals has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intercept Pharmaceuticals dividends.
If you bought $2,000 of Intercept Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intercept Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intercept Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ICPT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
United States of America Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 5932 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ICPT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 2.00
2019-12-31 0.00 3.00
2018-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intercept Pharmaceuticals has not reported any payouts.
  • Unable to verify if Intercept Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intercept Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intercept Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intercept Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable for United States of America.
X
Income/ dividend checks
We assess Intercept Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intercept Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intercept Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Intercept Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Pruzanski, image provided by Google.
Mark Pruzanski
COMPENSATION $6,154,687
AGE 49
TENURE AS CEO 16.4 years
CEO Bio

Dr. Mark Pruzanski, M.D., founded Intercept Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since 2002. Dr. Pruzanski serves as the President and Chief Executive Officer at MedicinePlanet, Inc. He has over 12 years of experience in life sciences startup management and venture capital, strategy consulting and healthcare policy. He co-founded Kirax Corporation (Alternate Name: Tigris Pharmaceuticals, Inc.) in 2005. He served as a Venture Partner at Apple Tree Partners (ATP), which he founded in 1999, where he worked with several portfolio companies to assist them in financing, strategic positioning and operations. Prior to that, he served at Oak Investment Partners in Connecticut as an Entrepreneur in Residence with a focus on sourcing technology and startup company origination. Dr. Pruzanski serves on the boards of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Foundation for Defense of Democracies. Dr. Pruzanski has been a Director of Intercept Pharmaceuticals, Inc. since 2002. He served as a Director of Evelo Biosciences, Inc. until March 16, 2017. He served as a Director of Evelo Therapeutics, Inc. since July 12, 2016 until January 31, 2017. He served as a Director and Observer at Kirax Corporation (Alternate Name: Tigris Pharmaceuticals, Inc.). Dr. Pruzanski is a Canadian Physician and received his M.D. from McMaster University in Ontario, an M.A. degree in International Affairs from the Johns Hopkins School of Advanced International Studies in Bologna, Italy and Washington, DC and a Bachelor's degree from McGill University in Montreal, Quebec.

CEO Compensation
  • Mark's compensation has increased whilst company is loss making.
  • Mark's compensation is higher than average for a company of this size and profit level.
Management Team Tenure

Average tenure and age of the Intercept Pharmaceuticals management team in years:

1.3
Average Tenure
48
Average Age
  • The average tenure for the Intercept Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Mark Pruzanski

TITLE
Founder
COMPENSATION
$6M
AGE
49
TENURE
16.4 yrs

Sandip Kapadia

TITLE
CFO, Treasurer & Principal Accounting Officer
COMPENSATION
$2M
AGE
47
TENURE
1.9 yrs

Jerry Durso

TITLE
Chief Operating Officer
COMPENSATION
$4M
AGE
49
TENURE
1.3 yrs

David Ford

TITLE
Chief Human Resources Officer
COMPENSATION
$2M
AGE
48
TENURE
1.1 yrs

David Shapiro

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
63
TENURE
11.1 yrs

Mark Vignola

TITLE
Director of Investor Relations

Ryan Sullivan

TITLE
General Counsel & Secretary
AGE
41
TENURE
0.3 yrs

Chris Weyer

TITLE
Executive Vice President of Research & Development
AGE
47
TENURE
0.6 yrs

Lisa Bright

TITLE
President of International
COMPENSATION
$2M
AGE
49
TENURE
1.9 yrs

Richard Kim

TITLE
President of U.S. Commercial & Strategic Marketing
AGE
48
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Intercept Pharmaceuticals board of directors in years:

3.3
Average Tenure
57.5
Average Age
  • The tenure for the Intercept Pharmaceuticals board of directors is about average.
Board of Directors

Paolo Fundaro

TITLE
Chairman of the Board
COMPENSATION
$394K
AGE
43
TENURE
2.7 yrs

Mark Pruzanski

TITLE
Founder
COMPENSATION
$6M
AGE
49
TENURE
16.4 yrs

Glenn Sblendorio

TITLE
Director
COMPENSATION
$385K
AGE
61
TENURE
4.3 yrs

Luca Benatti

TITLE
Director
COMPENSATION
$380K
AGE
56
TENURE
3.9 yrs

Gino Santini

TITLE
Director
COMPENSATION
$390K
AGE
60
TENURE
2.6 yrs

Dan Welch

TITLE
Director
COMPENSATION
$383K
AGE
59
TENURE
2.6 yrs

Scott Friedman

TITLE
Member of the Scientific Advisory Board

Massimo Pinzani

TITLE
Member of the Scientific Advisory Board

Aldo Roda

TITLE
Member of the Scientific Advisory Board

Alan Hofmann

TITLE
Member of the Scientific Advisory Board
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Intercept Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intercept Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) Shift From Loss To Profit

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT):. … The US$2.45b market-cap company’s loss lessens since it announced a -US$360.37m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$352.03m, as it approaches breakeven. … See our latest analysis for Intercept Pharmaceuticals

Simply Wall St -

Does Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) Earnings Growth Make It An Outperformer?

Assessing Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how Intercept Pharmaceuticals is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its biotechs industry peers. … Viewing growth from a sector-level, the US biotechs industry has been growing its average earnings by double-digit 21.75% in the past year, and 17.77% over the last five years.

Simply Wall St -

Breakeven On The Horizon For Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Check out our latest analysis for Intercept Pharmaceuticals According to the industry analysts covering ICPT, breakeven is near. … How fast will ICPT have to grow each year in order to reach the breakeven point by 2021? … Next Steps: This article is not intended to be a comprehensive analysis on ICPT, so if you are interested in understanding the company at a deeper level, take a look at ICPT’s company page on Simply Wall St.

Simply Wall St -

Intercept Pharmaceuticals Inc (NASDAQ:ICPT): What We Can Expect From This Growth Stock

Looking at Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) earnings update in December 2017, analyst consensus outlook appear cautiously optimistic, as a 12.43% increase in profits is expected in the upcoming year, relative to the past 5-year average growth rate of -34.70%. … In this article, I've outline a few earnings growth rates to give you a sense of the market sentiment for Intercept Pharmaceuticals in the longer term. … Future Earnings: How does Intercept Pharmaceuticals's growth rate compare to its peers and the wider market?

Simply Wall St -

Why Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) Ownership Structure Is Important

In this article, I will take a quick look at Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) recent ownership structure – an unconventional investing subject, but an important one. … Private Company Ownership Potential investors in ICPT should also look at another important group of investors: private companies, with a stake of 25.71%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: ICPT's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

What Investors Should Know About Intercept Pharmaceuticals Inc's (ICPT) Financial Strength

We can test the impact of these adverse events by looking at whether cash from its current operations can pay back its current debt obligations. … In the case of ICPT, operating cash flow turned out to be -0.96x its debt level over the past twelve months. … With a high level of debt on its balance sheet, ICPT could still be in a financially strong position if its cash flow also stacked up.

Simply Wall St -

Company Info

Map
Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Details
Name: Intercept Pharmaceuticals, Inc.
ICPT
Exchange: NasdaqGS
Founded: 2002
$2,509,226,243
29,582,955
Website: http://www.interceptpharma.com
Address: Intercept Pharmaceuticals, Inc.
10 Hudson Yards,
37th floor,
New York,
New York, 10001,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ICPT Common Stock Nasdaq Global Select US USD 11. Oct 2012
DB I4P Common Stock Deutsche Boerse AG DE EUR 11. Oct 2012
Number of employees
Current staff
Staff numbers
507
Intercept Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/06/20 23:26
End of day share price update: 2018/06/19 00:00
Last estimates confirmation: 2018/05/31
Last earnings update: 2018/03/31
Last annual earnings update: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.